Vontobel Holding’s CRISPR Therapeutics CRSP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$943K Buy
19,828
+6,826
+52% +$360K ﹤0.01% 671
2025
Q4
$682K Buy
13,002
+8,301
+177% +$497K ﹤0.01% 886
2025
Q3
$305K Buy
+4,701
New +$270K ﹤0.01% 1102
2025
Q2
Sell
-12,741
Closed -$434K 1270
2025
Q1
$434K Sell
12,741
-2,327
-15% -$98.6K ﹤0.01% 827
2024
Q4
$593K Sell
15,068
-1,889
-11% -$89.2K ﹤0.01% 749
2024
Q3
$797K Buy
16,957
+600
+4% +$30.4K ﹤0.01% 652
2024
Q2
$883K Sell
16,357
-1,450
-8% -$83.9K ﹤0.01% 595
2024
Q1
$1.21M Sell
17,807
-47
-0.3% -$3.37K 0.01% 531
2023
Q4
$1.12M Sell
17,854
-549
-3% -$30.4K 0.01% 564
2023
Q3
$835K Sell
18,403
-497
-3% -$25.7K 0.01% 625
2023
Q2
$1.06M Buy
18,900
+249
+1% +$14.1K 0.01% 587
2023
Q1
$844K Sell
18,651
-2,681
-13% -$130K 0.01% 631
2022
Q4
$836K Buy
21,332
+2,643
+14% +$140K 0.01% 617
2022
Q3
$1.22M Sell
18,689
-1,566
-8% -$113K 0.01% 503
2022
Q2
$1.28M Sell
20,255
-1,105
-5% -$65K 0.01% 486
2022
Q1
$1.37M Sell
21,360
-5,119
-19% -$321K 0.01% 534
2021
Q4
$2.09M Buy
26,479
+4,664
+21% +$407K 0.02% 426
2021
Q3
$2.44M Buy
21,815
+3,144
+17% +$395K 0.02% 406
2021
Q2
$2.81M Buy
+18,671
New +$2.27M 0.02% 372

Other funds holding CRSP

Vontobel Holding's CRSP Position: Q1 2026 in Review

Vontobel Holding increased its CRISPR Therapeutics (CRSP) stake by 52% in Q1 2026, buying an estimated $360K and bringing the position to 19,828 shares worth $943K. The position accounts for ﹤0.01% of the portfolio, ranked #671.

Vontobel Holding first reported a position in CRSP in Q2 2021 and has held it in 19 quarters since. The position peaked at $2.81M in Q2 2021. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Vontobel Holding held 19,828 shares of CRISPR Therapeutics worth $943K as of Q1 2026.
  • Vontobel Holding bought 6,826 CRISPR Therapeutics shares in Q1 2026, an estimated $360K.
  • CRISPR Therapeutics made up ﹤0.01% of Vontobel Holding's portfolio in Q1 2026, its #671 holding.
  • Vontobel Holding first reported a position in CRISPR Therapeutics in Q2 2021 and has held it in 19 quarters since.
  • Vontobel Holding's CRISPR Therapeutics position peaked at $2.81M in Q2 2021.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Vontobel Holding's 13F filing for Q1 2026, filed 8 May 2026.